Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland

Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland

BackgroundPersistence with antifibrotic medications in patients with idiopathic pulmonary fibrosis (IPF) is crucial for long-term outcomes. However, real-world data regarding treatment persistence patterns in IPF are scarce.MethodsWe conducted a post hoc analysis of two retrospective, real-world, mu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sebastian Majewski, Katarzyna Górska, Katarzyna B. Lewandowska, Magdalena M. Martusewicz-Boros, Małgorzata Sobiecka, Wojciech J. Piotrowski
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Pharmacology
Subjects:	idiopathic pulmonary fibrosis IPF antifibrotic therapy pirfenidone nintedanib treatment persistence
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1586197/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
by: Stefano Kette, et al.
Published: (2025-03-01)

Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis
by: Nesrin Ocal, et al.

Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?
by: Hikmet COBAN, et al.
Published: (2025-06-01)

Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study
by: Olcay Aycicek, et al.
Published: (2025-02-01)

Impact of Pirfenidone on Patient-Reported Outcomes in Patients With Idiopathic Pulmonary Fibrosis From the Pulmonary Fibrosis Foundation Patient RegistryTake-home Points
by: Mohleen Kang, MD, MS, et al.
Published: (2024-12-01)

Patient characteristics and pharmacologic treatment patterns in antifibrotic-treated patients with fibrosing interstitial lung diseases: real-world results from a claims database
by: Yasuhiro Kondoh, et al.
Published: (2025-05-01)

A clinical case of idiopathic pulmonary fibrosis against the background of comorbid pathology
by: A. V. Teteneva, et al.
Published: (2021-10-01)

Treatable traits in idiopathic pulmonary fibrosis: focus on respiratory tract infections—a systematic review and a meta-analysisResearch in context
by: Zsombor Matics, et al.
Published: (2025-01-01)

Perioperative Anti-Fibrotic Treatment Prevents Acute Exacerbation of Idiopathic Pulmonary Fibrosis After Lung Cancer Surgery
by: Stefano Bongiolatti, et al.
Published: (2024-11-01)

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France
by: Emilie Clay, et al.
Published: (2019-01-01)

Pulmonary fibrosis complicated by lung cancer: bibliometric analysis from 2004 to 2024 - research status, trends and future directions
by: Boyang Li, et al.
Published: (2025-04-01)

Prevention and Treatment of Peritoneal Dialysis-Associated Fibrosis with Intraperitoneal Anti-Fibrotic Therapy in Experimental Peritoneal Fibrosis
by: Chiao-Yin Sun, et al.
Published: (2025-01-01)

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases
by: Tao Wang, et al.
Published: (2025-04-01)

Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype
by: L. P. Ananieva, et al.
Published: (2021-01-01)

Quantitative micro-CT-derived biomarkers elucidate age-related lung fibrosis in elder mice
by: Davide Buseghin, et al.
Published: (2024-10-01)

INTERSTITIAL LUNG DISEASES: KEY TARGETS FOR THERAPY
by: N. A. Shostak, et al.
Published: (2018-06-01)

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology
by: E. L. Nasonov, et al.
Published: (2022-12-01)

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology
by: E. L. Nasonov, et al.
Published: (2018-06-01)

Physalis angulata Linn. As a Potential Liver Antifibrotic Agent In Rats.
by: Muhammad Begawan Bestari, et al.
Published: (2024-01-01)

Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis
by: Yiting Qiu, et al.
Published: (2025-07-01)

Apigenin as a multifaceted antifibrotic agent: Therapeutic potential across organ systems
by: Xiaoyong Hu, et al.
Published: (2025-06-01)

Exploring the Antifibrotic Mechanisms of Ghrelin: Modulating TGF-β Signalling in Organ Fibrosis
by: Mei Li, et al.
Published: (2025-01-01)

Successful Tepotinib Treatment in MET Exon 14 Skipping Mutation‐Positive Lung Adenocarcinoma With Idiopathic Pulmonary Fibrosis Through Nintedanib Combination
by: Yoshiki Kato, et al.
Published: (2025-06-01)

Pathogenesis and current status of the treatment of lung cancer associated with idiopathic pulmonary fibrosis
by: Yuanyuan Zhang, et al.
Published: (2025-07-01)

Trajectory of bodyweight and skeletal muscle mass in patients treated with nintedanib for idiopathic pulmonary fibrosis
by: Hiromi Tomioka, et al.
Published: (2024-12-01)

Persistent microbial infections and idiopathic pulmonary fibrosis - an insight into non-typeable Haemophilus influenza pathogenesis
by: Anthony Shadid, et al.
Published: (2024-12-01)

Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study
by: Camilla S. Graham, et al.
Published: (2025-05-01)

Affinity of Nintedanib Towards New Candidate Target for Idiopathic Pulmonary Fibrosis
by: Hari Baskar Balasubramanian, et al.
Published: (2024-08-01)

Nomogram model using serum Club cell secretory protein 16 to predict prognosis and acute exacerbation in patients with idiopathic pulmonary fibrosis
by: Yaqiong Tian, et al.
Published: (2025-01-01)

Air trapping in patients with idiopathic pulmonary fibrosis: a retrospective case—control study
by: Taehun Kim, et al.
Published: (2025-02-01)

Impact of antifibrotics on post-COVID-19 lung sequelae
by: Yosri Mohamed Kamel Akl, et al.
Published: (2025-06-01)

Identification of diagnostic hub genes related to energy metabolism in idiopathic pulmonary fibrosis
by: S. Zhao, et al.
Published: (2025-06-01)

Design, synthesis, and biological evaluation of ACF-03: a novel anti-fibrotic and antioxidant agent targeting ROS-TGF-β1-HIF-1α axis
by: Hiruni Nilshi Indeevarie Abeysiriwardhana, et al.
Published: (2025-07-01)

Idiopathic Pulmonary Fibrosis, Today and Tomorrow: Certainties and New Therapeutic Horizons
by: Giacomo Giulianelli, et al.
Published: (2025-05-01)

Acneiform drug eruption from pirfenidone
by: Jordyn Puccio, BS, et al.
Published: (2025-07-01)

Ferroptosis in idiopathic pulmonary fibrosis: mechanisms, impact, and therapeutic opportunities
by: Mingjun Yao, et al.
Published: (2025-05-01)

Comparing survival outcomes of anti-fibrotic therapy for idiopathic pulmonary fibrosis with and without emphysema: a multi-center real-world study from Taiwan
by: Yu-Hung Fang, et al.
Published: (2025-08-01)

The immune mechanisms of acute exacerbations of idiopathic pulmonary fibrosis
by: Tao Chen, et al.
Published: (2024-12-01)

Comparative efficacy of Pirfenidone and Meloxicam on early radiotherapy-induced anal sphincter dysfunction in rats
by: Dragoș Viorel Scripcariu, et al.
Published: (2025-03-01)

Investigates the Role of PANoptosis in Idiopathic Pulmonary Fibrosis and Potential Therapeutic Targets
by: Xiang Y, et al.
Published: (2024-12-01)